Physician profile
Anthony Henry
NPI 1245232487
$7,537.59
in general payments reported to CMS, 2019-2025
33 companies · $1,310 in 2025
The $1,310 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $787 · 2020: $883 · 2021: $1,241 · 2022: $1,355 · 2023: $957 · 2024: $1,004 · 2025: $1,310.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,132 · Education: $139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,132.04 |
| Education | $139.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,197.10 | 2019-2025 | Fasenra, Tezspire, Breztri |
| Glaxosmithkline, LLC. | $2,146.91 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Genzyme Corporation | $778.92 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $314.24 | 2020-2024 | Cuvitru |
| Regeneron Healthcare Solutions, INC. | $287.15 | 2019-2025 | Dupixent |
| Amgen INC. | $242.91 | 2021-2025 | Tezspire |
| Octapharma USA, INC. | $203.21 | 2021-2023 | Panzyga |
| Mylan Specialty L.P. | $169.11 | 2019-2024 | Yupelri |
| Kaleo, INC. | $133.07 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $122.73 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.27 | 2019-2022 | |
| Verona Pharma, INC. | $91.63 | 2025 | Ohtuvayre |
| Genentech USA, INC. | $89.59 | 2020-2022 | |
| Csl Behring | $82.59 | 2025 | Hizentra, Andembry |
| Ionis Pharmaceuticals, INC. | $71.58 | 2025 | Dawnzera, Donidalorsen |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $64.58 | 2019-2023 | |
| Alk-Abello, INC | $57.72 | 2022-2023 | Ragwitek, Grastek, Odactra |
| Biocryst US Sales Co., LLC | $44.47 | 2021-2022 | |
| Optinose US, INC. | $37.47 | 2025 | |
| Grifols USA, LLC | $35.84 | 2019-2021 | |
| Azurity Pharmaceuticals, INC. | $35.43 | 2025 | Alvesco |
| Hikma Pharmaceuticals USA | $33.50 | 2023 | Ryaltris |
| Incyte Corporation | $23.64 | 2021 | |
| Ars Pharmaceuticals Operations, INC. | $22.61 | 2025 | Neffy |
| Phadia US INC. | $20.94 | 2022 | |
| Uswm, LLC | $20.00 | 2021 | |
| Blueprint Medicines Corporation | $18.72 | 2022 | |
| Abbvie INC. | $17.81 | 2021 | |
| Novartis Pharmaceuticals Corporation | $15.98 | 2025 | |
| Merck Sharp & Dohme LLC | $15.87 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $15.85 | 2020 | |
| Shire North American Group INC | $15.54 | 2019 | |
| Eyevance Pharmaceuticals LLC | $14.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Henry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.